Q-omics provides the consensus-scored GABRQ profile across patient tissues and cancer cell-line models. GABRQ expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GABRQ is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, GABRQ RNA expression shows 16,977 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where GABRQ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GABRQ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GABRQ survival associations across molecular data types. GABRQ RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GABRQ RNA expression–survival associations across cancer types. High GABRQ expression shows unfavorable associations in KIRP, UVM, STAD, BRCA and ACC, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GABRQ RNA expression.
This table summarizes GABRQ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GABRQ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GABRQ shows higher tumor expression in HNSC, KIRC, LIHC, LUSC, LUAD and BRCA. The HNSC box plot shows higher GABRQ RNA expression in tumor versus normal tissue (log2 FC = +1.184, t-test p < 0.001).
This table shows molecular features associated with GABRQ in patient tissues and cancer cell lines. In patient samples, GABRQ shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GABRQ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
